STOCK TITAN

Immatics N.V - IMTX STOCK NEWS

Welcome to our dedicated news page for Immatics N.V (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immatics N.V's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immatics N.V's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
Immatics N.V

Nasdaq:IMTX

IMTX Rankings

IMTX Stock Data

1.09B
76.56M
25.69%
50.65%
8.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Germany
Tuebingen

About IMTX

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics'​ proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l